Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma

Acral Lentiginous Melanoma Clinical Trial

Official title:
An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma

Status Completed

Clinical Trial Summary

To determine the Overall Response Rate (ORR), as defined as rate of complete response (CR) and partial response (PR) as per RECIST 1.1 in biological treatment-naïve patients with acral lentiginous melanoma treated with pembrolizumab

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02875132
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	Phase 2
Start date	February 15, 2017
Completion date	February 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03025256` - Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease	Phase 1
Terminated	`NCT02978443` - A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab	Phase 2
Active, not recruiting	`NCT00937937` - Dinaciclib in Treating Patients With Stage IV Melanoma	Phase 2
Recruiting	`NCT04511013` - A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases	Phase 2
Active, not recruiting	`NCT03698019` - A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma	Phase 2
Terminated	`NCT04244552` - A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Phase 1